Invivyd (IVVD) Assets Average (2021 - 2026)
Invivyd's (IVVD) quarterly Assets Average came in at $247.9 million in Q2 2026, up 157.03% on a YoY basis from $96.4 million in Q2 2025, and up 19.16% quarter-over-quarter from $208.0 million in Q4 2025.
Analysis
Invivyd (IVVD) Assets Average (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Assets Average for 6 consecutive years, with $247.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets Average rose 157.03% year-over-year to $247.9 million; the trailing twelve-month figure through Jun 2026 stood at $247.9 million (up 157.03% YoY), and the FY2025 full-year result was $203.2 million, up 13.3% from the prior year.
- Assets Average advanced to $247.9 million in Q2 2026 per IVVD's latest filing, from $208.0 million in the prior quarter.
- Across five years, Assets Average topped out at $588.2 million in Q1 2022 and bottomed at $96.4 million in Q2 2025.
- Historically, Assets Average has averaged $278.3 million across 5 years, with a median of $247.9 million in 2026.
- The sharpest annual moves came in 2025 and 2026: Assets Average slumped 50.9% in 2025, then jumped 157.03% in 2026.
- Over 5 years, Assets Average stood at $404.0 million in 2022, then slumped by 37.6% to $252.0 million in 2023, then slumped by 42.19% to $145.7 million in 2024, then jumped by 42.76% to $208.0 million in 2025, then increased by 19.16% to $247.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $247.9 million, $208.0 million, and $114.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 247.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 247.88 Mn |
| Dec 31, 2025 | 208.02 Mn |
| Sep 30, 2025 | 114.15 Mn |
| Jun 30, 2025 | 96.44 Mn |
| Mar 31, 2025 | 116.63 Mn |
| Dec 31, 2024 | 145.72 Mn |
| Sep 30, 2024 | 169.63 Mn |
| Jun 30, 2024 | 196.41 Mn |
| Mar 31, 2024 | 222.32 Mn |
| Dec 31, 2023 | 252.05 Mn |
| Sep 30, 2023 | 295.17 Mn |
| Jun 30, 2023 | 332.99 Mn |
| Mar 31, 2023 | 366.87 Mn |
| Dec 31, 2022 | 403.96 Mn |
| Sep 30, 2022 | 454.68 Mn |
| Jun 30, 2022 | 520.44 Mn |
| Mar 31, 2022 | 588.18 Mn |
| Dec 31, 2021 | 653.18 Mn |
| Sep 30, 2021 | 542.13 Mn |